GSK scores with a promise of success in the fight against CRSwNP

The British pharmaceutical giant GSK recently presented promising results from the Phase III studies ANCHOR-1 and ANCHOR-2 for its drug Depemokimab, which was tested in adults with chronic rhinosinusitis and nasal polyps. The two parallel studies assessed the efficacy and safety of Depemokimab compared to a placebo, involving a total of 271 and 257 participants, respectively. The studies achieved their primary endpoints and demonstrated significant improvement in patients treated with Depemokimab compared to the placebo group. After 52 weeks, a significant reduction in the endoscopic nasal polyp score and an improvement in the degree of nasal congestion were observed. GSK emphasizes that these results could indicate a potential advancement in the treatment of CRSwNP. While similar side effects were noted in both treatment arms, the data are currently being analyzed in more detail. Depemokimab stands out as a long-acting biologic with a unique affinity for interleukin-5 (IL-5) and offers a semi-annual dosing schedule, which could provide a convenient treatment option for patients. The results from the ANCHOR studies, along with data from the SWIFT-1 and SWIFT-2 studies in severe asthma, will form the basis for future regulatory submissions. Kaivan Khavandi, Senior Vice President at GSK, expressed encouragement over the study results and sees great potential in the targeted suppression of inflammatory processes that promote the growth of nasal polyps.